Our Story
Avenna was spun out from Ludger in 2017 to translate a promising glycomic research programme into practical and affordable diagnostic tools for inflammatory diseases. We are now working with scientists, clinicians, academics and patient groups, to further develop this assay into precision medicine clinical biomarkers and tests to enable early detection and treatment personalisation for inflammatory diseases.
Mission
Avenna translates most promising research grade technologies into practical, affordable, and accessible clinical tools to enable precision medicine approach to treat inflammatory diseases. Our midterm goal is to further develop and commercialise, blood glycomic biomarkers for inflammatory bowel, brain, and skin diseases.
Vision
To become a world leader in development of personalised precision healthcare solutions for inflammatory diseases. These solutions will enable early detection, treatment personalisation for individuals living with inflammatory conditions, will increase their healthspan and reduce healthcare costs.Who can benefit from GlyHealth?
Our group of prognostic and predictive blood biomarkers – GlyHealth, reliably measure and track chronic inflammation processes in the body. Unlike current inflammation markers, this is done without interference from acute inflammation and can give early warning signs even at very early subclinical stages of inflammatory diseases.
We empower patients, clinicians, and the pharmaceutical industry by advancing biomarker-driven solutions for chronic inflammatory diseases (CIDs). Our biomarkers enable early detection, disease monitoring, and personalized treatment strategies for a range of conditions, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA).
Benefits for Individuals:
- Reliable tracking of chronic inflammation
- Accelerated disease diagnosis
- Personalised treatment and therapy monitoring
Benefits for Clinicians:
- Improved patient triage and tailored treatment strategies
- Early detection of disease flares
- A proactive, personalised approach to managing CIDs
Benefits for Pharma & Biopharma:
- Optimised clinical trials for anti-inflammatory therapeutics through precise patient selection
- Robust, reliable evidence of drug efficacy
- Increased likelihood of regulatory approval
Our Team
A passionate team with technology, clinical and scientific expertise.
Chief Executive Officer, Avenna Ltd
Chief Science Officer,
Avenna Ltd
Chief Executive Office,
Ludger Ltd
Project Manager,
Avenna Ltd
Ludger is a UK-based biotechnology company, with a 25 years of experience in glycoprofiling technologies, reagents, and services for biopharmaceuticals and medical research. We work closely together with their R&D team to develop precision medicine solutions.